UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016086
Receipt number R000018679
Scientific Title Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
Date of disclosure of the study information 2014/12/30
Last modified on 2021/02/25 14:37:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer

Acronym

S-1 for adjuvant chemotherapy in NSCLC

Scientific Title

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer

Scientific Title:Acronym

S-1 for adjuvant chemotherapy in NSCLC

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to determine the feasible adjuvant therapy administration schedule of S-1 for completely resected non-small cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Cumulative rate of total administration days of S-1, relative dose intensity, and adverse events

Key secondary outcomes

Three-year-relapse free survival


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Arm A receiving oral S-1 of 4-week administration followed by 2-week rest for 12 months

Interventions/Control_2

Arm B receiving oral S-1 of 2-week administration followed by 1-week rest for 12 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Completely resected non-small cell lung cancer
2) Adenocarcinma, large cell carcinoma, squamous cell carcinoma, or adeno-squamous cell carcinoma
3) Stage IB-IIIA
4) Age 20-75 year-old
5) ECOG Perfomance Status 0-1
6) Adequate organ function
7) Able to start within 9 weeks after the surgery
8) No prior therapy
9) Written informed concent

Key exclusion criteria

1) Interstitial pneumonia
2) Pleural effusion, ascites, cardiac effusion
3) Active double malignancies
4) Serious medical complications
5) Diarrhea
6) Pregnancy, breastfeeding or suspected of being pregnant
7) Male with intent of reproduction
8) Drug allergy
9) Allergy to ingredients of S-1
10) Administering fluorinated pyrimidine other than S-1
11) Administering flucytosine
12) Others judged by attending physician

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Akira
Middle name
Last name Iyoda

Organization

Toho University Omori Medical Center

Division name

Division of Chest Surgery

Zip code

143-8541

Address

6-11-1 Omori-nishi, Ota-ku, Tokyo

TEL

03-3752-4151

Email

aiyoda@med.toho-u.ac.jp


Public contact

Name of contact person

1st name Yoshinobu
Middle name
Last name Hata

Organization

Toho University Omori Medical Center

Division name

Division of Chest Surgery

Zip code

143-8541

Address

6-11-1 Omori-nishi, Ota-ku, Tokyo

TEL

03-3752-4151

Homepage URL


Email

hata@med.toho-u.ac.jp


Sponsor or person

Institute

Division of Chest Surgery, Toho University Omori Medical Center

Institute

Department

Personal name



Funding Source

Organization

Division of Chest Surgery, Toho University Omori Medical Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Division of Surgery, Toho University Ohashi Medical Center
Division of Surgery, Toho University Sakura Medical Center
Department of Thoracic Surgery, National Defense Medical College Hospital
Department of Thoracic and Cardiovascular Surgery, Self-Defense Forces Central Hospital
Division of Respiratory Medicine, Toranomon Hospital
Respiratory Diseases Center, International University of Health and Welfare, Mita Hospital
Department of Thoracic Surgery, Mitsui Memorial Hospital
Division of Thoracic and Cardiovascular Surgery, Showa University School of Medicine

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization

the Ethics Committee of Toho University Omori Medical Center

Address

6-11-1 Omori-nishi, Ota-ku, Tokyo

Tel

03-3762-4151

Email

somu.omori@jim.toho-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 30 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pubmed/28851314

Number of participants that the trial has enrolled

80

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results

2017 Year 08 Month 29 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2005 Year 04 Month 01 Day

Date of IRB

2004 Year 03 Month 16 Day

Anticipated trial start date

2005 Year 04 Month 01 Day

Last follow-up date

2016 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 30 Day

Last modified on

2021 Year 02 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018679


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name